EUVIMEDEUVIMED entdecken
Kohortenstudie

Prognostic utility of HALP score in predicting post-chemotherapy recurrence in testicular cancer: A retrospective cohort study

Kemal Kayar, Ridvan Kayar, Emre Karabay, Behlul Berk Genc, Çağatay Tosun, Ömer Ergin Yücebaş

Marmara Medical Journal · 21.05.2026 · 39 (2) · 85-91

DOI: 10.5472/marumj.1951401 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Marmara Medical Journal, online erschienen am 21.05.2026. Verfasst von Kemal Kayar und 5 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is an inflammation – and nutrition-based biomarkerassociated with prognosis in various malignancies. Its role in predicting post-chemotherapy recurrence in testicular germ cell tumors(TGCT) remains unclear. This study evaluated the prognostic value of the HALP score after cisplatin-based chemotherapy and itsadditional contribution beyond clinical staging.Patients and Methods: This retrospective cohort included 91 TGCT patients treated with orchiectomy and cisplatin-based chemotherapybetween 2015 and 2023. Clinical, pathological, and hematologic data were collected. HALP, neutrophil-to-lymphocyte ratio (NLR),and systemic immune-inflammation index (SII) were calculated from pre-treatment laboratory values. Recurrence-free survival(RFS) was analyzed using Kaplan–Meier and Cox regression models. Receiver operating characteristic (ROC) analysis determined theoptimal HALP cut-off.

Results

Recurrence occurred in 14 patients (15.4%). Patients with recurrence had significantly lower baseline HALP scores. Theoptimal HALP cut-off was 53.615 (AUC=0.699). Higher HALP scores were associated with improved 3 – and 5-year RFS. HALP, NLR,SII, and advanced stage were significant in univariate analyses; however, only stage remained independently predictive in multivariatemodels.

Conclusion

Lower pre-treatment HALP scores were associated with increased recurrence risk and inferior long-term RFS. HALP mayprovide complementary prognostic information within stage-defined groups.

Zitieren

APA

Kayar, K., Kayar, R., Karabay, E., Genc, B. B., Tosun, Ç., & Yücebaş, Ö. E. (2026). Prognostic utility of HALP score in predicting post-chemotherapy recurrence in testicular cancer: A retrospective cohort study. Marmara Medical Journal, 39(2), 85-91. https://doi.org/10.5472/marumj.1951401

Vancouver

Kayar K, Kayar R, Karabay E, Genc BB, Tosun Ç, Yücebaş ÖE. Prognostic utility of HALP score in predicting post-chemotherapy recurrence in testicular cancer: A retrospective cohort study. Marmara Medical Journal. 2026;39(2):85-91. doi:10.5472/marumj.1951401

BibTeX
@article{Kayar2026,
  author = {Kayar, Kemal and Kayar, Ridvan and Karabay, Emre and Genc, Behlul Berk and Tosun, Çağatay and Yücebaş, Ömer Ergin},
  title = {Prognostic utility of HALP score in predicting post-chemotherapy recurrence in testicular cancer: A retrospective cohort study},
  journal = {Marmara Medical Journal},
  year = {2026},
  volume = {39},
  number = {2},
  pages = {85--91},
  doi = {10.5472/marumj.1951401}
}
Kostenlos starten →